BRAF V600E is the genetic lesion underlying hairy-cell leukemia. We assessed the safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairycell leukemia that had relapsed after treatment with a purine analogue or who had disease that was refractory to purine analogues.
n engl j med 373;18 nejm.org October 29, 2015 H airy-cell leukemia is a chronic mature B-cell cancer with unique clinicopathologic and biologic features. [1] [2] [3] [4] Purine analogues (cladribine and pentostatin) induce durable complete responses in approximately 80% of patients with this cancer. 5, 6 However, in 30 to 50% of patients, the disease relapses and there is a progressively worse response to purine analogues, 7, 8 which can also cause cumulative myelotoxic effects and immune suppression. Thus, new therapeutic approaches are needed.
Tiacci and colleagues found that the V600E mutation of BRAF, a kinase commonly mutated in solid tumors, 9 was the key genetic lesion of hairy-cell leukemia, 10, 11 and Chung et al. found that this mutation is acquired in the hematopoietic stem-cell compartment. 12 Tiacci et al. found that, as in other BRAF-mutated neoplasms, 13 the V600E mutation in hairy-cell leukemia constitutively activates the mitogen-activated protein kinase (MAPK) pathway. 14, 15 The same group found that BRAF inhibitors in vitro 16 reverse the unique molecular signature 2 and morphologic characteristics of hairy cells and potently induce their apoptosis, thus establishing BRAF V600E as an attractive therapeutic target in hairy-cell leukemia. Moreover, the antileukemic activity of BRAF inhibitors has been reported anecdotally in patients with this cancer. 17, 18 We conducted two phase 2, multicenter clinical trials -in Italy and the United States -to investigate the efficacy and safety of an oral BRAF inhibitor, vemurafenib, 19 in patients with relapsed or refractory hairy-cell leukemia. The enrollment of patients in the Italian trial was completed in April 2013, and the median followup is almost 2 years after the end of treatment. The enrollment of the patients in the U.S. trial has not yet been completed, but the primary end point (overall response rate) has already been met. Here we report the results of these two trials.
Me thods

Patients
In the Italian trial, 28 patients were enrolled (Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org). All the patients met one of the following criteria: disease that was refractory to a purine analogue, defined as no response or a relapse within 1 year after treatment (6 patients); early relapse after treatment with a purine analogue, defined as re-lapse that occurred between 1 and 2 years after the first course or within 4 years after a second or later course (20 patients) or in any case (regardless of timing) in which there was considerable bone marrow hypoplasia at the time of relapse (1 patient); or severe side effects from a previous purine analogue (1 patient) . Eligible patients also had to have a hemoglobin level of less than 11.0 g per deciliter, a neutrophil count of less than 1500 per cubic millimeter, or a platelet count of less than 100,000 per cubic millimeter. The diagnosis was confirmed centrally by two of the authors with the use of annexin A1 immunostaining of a bone marrow-biopsy specimen, 20 detection of BRAF V600E by an allele-specific polymerase-chain-reaction (PCR) assay, 11 and flow cytometry. Further details are provided in the study protocol, available at NEJM.org.
In the U.S. trial, 26 patients have been enrolled ( Table S2 in the Supplementary Appendix).
All the patients met one of the following criteria: disease that was refractory to a purine analogue (as defined above; 1 patient); early relapse (between 1 and 2 years) after the first course of a purine analogue (1 patient); or two or more relapses that occurred more than 2 years after a third or later course of a purine analogue (24 patients). Eligible patients had to have a hemoglobin level of 10.0 g per deciliter or less, a neutrophil count of 1000 per cubic millimeter or less, or a platelet count of 100,000 per cubic millimeter or less. The presence of BRAF V600E was assessed by means of immunohistochemical testing, PCR assay or Sanger sequencing, or the Memorial Sloan Kettering Cancer Center IMPACT assay 21 (the IMPACT assay was performed in all the patients) in a Clinical Laboratory Improvement Amendments-certified laboratory. Further details are provided in the study protocol.
Study Design
The Italian trial was a phase 2, single-group, multicenter study sponsored by the Institute of Hematology, University of Perugia, and designed by the first and penultimate authors. Roche provided an unconditional research grant and vemurafenib at no cost. Otherwise, Roche had no role in the study. The planned enrollment of 28 patients was completed in 11 months (May 20, 2012, through April 23, 2013) at eight centers. Patients received oral vemurafenib at a dose of 960 mg twice daily for a minimum of 8 weeks and, if they did not have a complete response, for a maximum of 16 weeks ( Fig. S1 in the Supplementary Appendix). The first 3 patients received vemurafenib for 20 weeks. The primary end point was the rate of complete response. Secondary end points included the time to response, relapse-free survival, and safety. We also evaluated the overall response rate, progressionfree survival, treatment-free survival (i.e., from the last vemurafenib dose until the initiation of further antileukemic treatment), and pharmacodynamic biomarkers. The U.S. trial is an ongoing phase 2, singlegroup, multicenter study that was designed by the second and last authors. The role of Roche is the same as that in the Italian trial. The patients were enrolled consecutively from January 2013 through February 2015 at six sites. Patients received oral vemurafenib at a dose of 960 mg twice daily, on a continuous schedule for 12 weeks. Patients with residual disease (as assessed by means of morphologic or immunohistochemical testing for CD20, PAX5, DBA44, and tartrateresistant alkaline phosphatase) were allowed to receive vemurafenib for up to 12 additional weeks. The primary end point was the overall response rate after 12 weeks of treatment with vemurafenib. Secondary end points were overall survival, progression-free survival, time to relapse, and pharmacodynamic outcomes.
In the two trials, treatment with vemurafenib was allowed at the time of disease relapse, which was defined as peripheral-blood counts that were low enough to meet the respective initial eligibility criteria. Retreatment was permitted for up to 12 weeks (in the Italian trial) or until disease progression or occurrence of an unacceptable level of toxic effects (in the U.S. trial).
Study Assessments
Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. Neoplastic cutaneous lesions were surgically excised, but their presence did not mandate dose modifications.
In the Italian trial, assessments of response (blood counts, spleen size, bone marrow biopsy, and aspirate) were conducted monthly during treatment, together with a dermatologic examination, and every 3 months during follow-up (except for the bone marrow evaluation, which was performed every 6 months). Bone marrow and peripheral-blood samples were assessed centrally at the Institute of Hematology, University of Perugia. The calculation of the Hairy Cell Index (the percentage of hematopoietic cellularity multiplied by the percentage of leukemic cells, as assessed on the basis on CD20 immunostaining, and divided by 10,000) in the bone marrow-biopsy specimen has been described previously. 22 In the U.S. trial, bone marrow assessments were performed after 1 and 3 months of vemurafenib treatment and at the end of treatment. For patients who had splenomegaly at enrollment, computed tomography of the abdomen was performed at baseline and at 3 months. All the patients underwent dermatologic examination at baseline, after 1 month of vemurafenib treatment, and every 3 months thereafter until at least 1 year after discontinuation of the drug.
In the two trials, the assessment of a complete response required the resolution of any cytopenias (as defined by the eligibility criteria in each of the two studies) , the absence of evidence of hairy cells in the peripheral blood and in bone marrow-biopsy specimens as assessed by means of nonimmunologic stains, and the absence of splenomegaly. The assessment of a partial response required the resolution of cytopenias, a reduction in splenomegaly of at least 50%, and a reduction of at least 50% in leukemic-cell infiltration in both the bone marrow and peripheral blood. In the two trials, relapse after a complete or partial response was defined as the reappearance of cytopenia on at least two consecutive occasions (the first of which was considered to be the date of relapse).
Pharmacodynamic Analyses
Changes in the morphologic features of the leukemia cells during vemurafenib exposure and bone marrow ERK phosphorylation at the end of treatment (as assessed by two investigators in a blinded manner) were evaluated as described previously. 14, 16 The leukemia disease burden was assessed by means of serial flow cytometric analysis of peripheral-blood mononuclear cells (PBMCs) or bone marrow mononuclear cells. 5, 23 DNA from PBMCs was used to quantify the BRAF V600E allele burden with the use of a droplet digital PCR assay. Soluble interleukin-2-receptor alpha (IL2RA) and interleukin-1 receptor type II were measured in serum. 24 Targeted genomic analysis was performed in PBMCs as described n engl j med 373;18 nejm.org October 29, 2015 previously. 25 Further details are provided in the Methods section in the Supplementary Appendix.
Statistical Analysis
A Simon's minimax two-stage design 26 was adopted in the two trials. In the Italian study, we calculated a sample size that would be sufficient to accept the alternative hypothesis (complete response rate, ≥30%) and reject the null hypothesis (complete response rate, ≤10%) in an intention-to-treat analysis, at an alpha level of 0.05 and a beta level of 0.2. Enrollment was closed in April 2013, when the prespecified number of patients (28 patients) had been enrolled.
In the U.S. study, the primary end point was the overall response rate at 12 weeks. A Simon's minimax two-stage design was used to differen-tiate between a promising response rate of 40% and an unpromising rate of 20%. In the initial stage of the study, we determined that a total of 19 patients had to be enrolled; if 4 or more patients had a response, the study would continue enrolling, with a target final sample of 36 patients. The study would be considered a success if at least 11 of the 36 patients had a response. Type I and type II errors were both 0.10. Because of promising results (24 patients with a response), this report includes data on the first 26 patients enrolled.
In the two trials, survival was estimated with the use of the Kaplan-Meier method. In the Italian study, differences in the rate of survival were assessed by means of a two-sided log-rank test. In the U.S. study, the time to relapse was evaluated with the use of cumulative incidence functions that treated death in the absence of relapse as a competing risk.
The change in hairy-cell leukemia cells in peripheral blood and bone marrow and the ratio of BRAF V600E to BRAF wild-type DNA concentration at 12 weeks were evaluated with the use of a paired Student's t-test. Full details of the statistical analysis are provided in the Supplementary Appendix.
R esult s
Patients
The characteristics of all 54 patients are shown in Table 1 and in Tables S1 and S2 in the Supplementary Appendix. Six patients in the Italian study and 1 in the U.S. study had disease that was refractory to a purine analogue; these patients had undergone a median of 2.5 prior therapies and 1 prior therapy, respectively, before vemurafenib treatment. Patients who had an early or repeated relapse after treatment with a purine analogue (20 patients in the Italian study and 25 patients in the U.S. study) had received a median of 4 prior therapies and 3 prior therapies, respectively. A total of 54% of the patients in the Italian study (15 of 28 patients) and 41% of those in the U.S. study (9 of 22) had disease that was refractory to the immediate prior therapy.
In the Italian trial, 26 of 28 patients completed the planned treatment (median duration of treatment, 16 weeks; range, 8 to 20). A total of 2 patients discontinued the study treatment at or before 1 week, owing to acute myocardial infarction (in 1 patient), which was considered by the investigator to be unrelated to the study drug, and to withdrawal of consent after a drug-related event of grade 3 reversible pancreatitis (in 1). In the U.S. trial, 24 of 26 patients received the study treatment for a median of 18 weeks (range, 12 to 24). One patient died from progressive pneumonia (which was considered by the investigator to be unrelated to the study drug) after 23 days of treatment, and another patient withdrew consent after 4 weeks owing to a drugrelated event of grade 3 reversible photosensitivity.
Response Rate
The overall response rates were 96% (25 of 26 patients who could be evaluated) in the Italian study and 100% (24 of 24) in the U.S. study. The unusual presenting features of the one patient who did not have a response are described in the Results section in the Supplementary Appendix.
The rates of complete response were similar in the two trials, as were the rates of partial response. In the Italian study, after a median of 8 weeks, 35% of the patients (9 of 26) had a complete response and 62% (16 of 26) had a partial response (Table S1 in the Supplementary Appendix). Among the patients with a complete response, 1 had primary refractory disease, and among those with a partial response, 5 had primary refractory disease. A total of 4 patients with a complete response and 10 with a partial response had disease that was resistant to the last prior treatment.
The median time to recovery of the platelet count (≥100,000 per cubic millimeter) was 2 weeks, the median time to recovery of the neutrophil count (≥1500 per cubic millimeter) was 4 weeks, and the median time to recovery of the hemoglobin level (≥11.0 g per deciliter) was 8 weeks. Reversion of symptomatic splenomegaly and clearance of leukemia cells from the blood (as assessed by means of cytomorphologic testing) usually occurred within 2 weeks after the start of treatment. A substantial decrease in leukemic-cell infiltration into bone marrow was observed at the earliest time point evaluated (4 weeks) (data not shown). However, in all the patients with a complete response, immunohistochemical testing showed minimal residual disease (≤10% of leukemic cells) at the end of treatment ( Fig. 1A and 1B) .
In the U.S. trial, after 12 weeks of vemurafenib treatment, 42% of the patients (10 of 24 patients) had a complete response and 58% (14 of 24) had a partial response ( Table S2 in the Supplementary Appendix). Most patients had recovery of the neutrophil count (>1000 per cubic millimeter), the hemoglobin level (>10.0 g per deciliter), and the platelet count (>100,000 per cubic millimeter) by 28 days ( Fig. 2A) . Among the 10 patients who received vemurafenib at a twice-daily dose of 480 mg for more than 4 weeks, rates of complete response (40%) and partial response (60%) were similar to those observed among patients who received the standard dose.
In unplanned exploratory analyses in the two studies, treatment duration did not appear to influence the type of response (see the Supplementary Appendix). In addition, the rate of complete response was not associated with status with regard to prior splenectomy, burden of bone marrow disease, refractoriness of the disease to the last treatment, or number of prior therapies (Tables S1 and S2 in the Supplementary Appendix, and data not shown).
Response Duration
In the Italian study, the median follow-up of the 25 patients who had a response was 23 months (range, 7 to 28) after the last vemurafenib dose. The median relapse-free survival was 9 months; the relapse-free survival was significantly longer among patients who had a complete response than among those who had a partial response (19 months vs. 6 months; hazard ratio for relapse, 0.26; 95% confidence interval [CI], 0.10 to 0.68; P = 0.006) (Fig. 1C ). The median treatmentfree survival was 21.5 months in all 26 patients who could be evaluated, and (with the limitation of small numbers) it did not differ significantly between the group of patients who had a complete response and the group of those who had a partial response (25 months and 18 months, respectively; P = 0.21) ( Fig. 1C) .
Of the 20 patients who had a relapse (5 patients after a complete response and 15 after a partial response), 7 did not require therapy at a median of 15 months (range, 4 to 18) after relapse, because their cytopenias were stably mild (median hemoglobin level, 14 at a median of 5 months (range, 0 to 16) after relapse.
A total of 5 of 25 patients (4 patients with a complete response and 1 with a partial response) had not had a relapse as of the last follow-up assessment (23 to 25 months after the end of treatment). Of the 4 patients with a com-plete response, 3 had no morphologic evidence of hairy-cell leukemia in their last bone marrow-biopsy specimen at 13, 19, and 24 months, respectively, whereas the fourth patient did not have a complete response on histologic testing at 12 months but did have normal blood counts at the last follow-up (24 months). In unplanned exploratory analyses, relapsefree survival and treatment-free survival did not differ significantly between the group of 18 patients who received additional treatment after having their best response and the group of 7 patients who did not receive additional treatment, or between the group of 14 patients who required a dose reduction and the group of 11 who did not (data not shown). However, the 7 patients who underwent splenectomy had a shorter relapse-free survival than did those who did not undergo splenectomy (median, 6 months vs. 11 months; hazard ratio for relapse, 3.55; 95% CI, 1.04 to 12.06; P = 0.04) and shorter treatment-free survival (median, 11 months vs. 25 months; hazard ratio, 6.61; 95% CI, 1.56 to 28.00; P = 0.01).
In the U.S. trial, among survivors at the time of data cutoff, the median follow-up from the first vemurafenib dose was 11.7 months (range, 1.3 to 25.4). At 1 year, the rate of progressionfree survival was 73% (95% CI, 55 to 97) and the rate of overall survival was 91% (95% CI, 79 to 99) ( Fig. 2B ). Disease progression occurred in 7 of 24 patients (29%), including 3 patients who had had a complete response and 4 who had had a partial response ( Table S2 in the Supplementary Appendix). At 1 year after response, the cumulative incidence of relapse was 27% (95% CI, 7 to 51). In both trials, vemurafenib retreatment at the time of relapse produced some responses (see the Supplementary Appendix). Table 2 lists the drug-related adverse events of grade 2 or higher that were observed in at least 1 patient in either trial. Table S3 in the Supplementary Appendix list all the adverse events of any grade in the Italian trial, including those that were not considered by the investigator to be related to the study drug. Table S4 in the Supplementary Appendix lists drug-related adverse events in the U.S. trial that occurred in more than 5% of the 26 patients, as well as all adverse events of secondary neoplasms.
Adverse Events
In both trials, common vemurafenib-related adverse events, mostly of grade 1 or 2 and all reversible, included toxic events of the skin (especially rash and photosensitivity), arthralgias or arthritis, pyrexia, and an elevated bilirubin level. Other relatively frequent drug-related adverse events (recorded in one or both studies) were skin papillomas, alopecia, palmar or plantar hyper-keratosis or dysesthesia, and fatigue, as well as an increase in the serum lipase level (which in 2 patients was associated with grade 3 pancreatitis) and elevated levels of aminotransferases, alkaline phosphatase, or fibrinogen.
In the Italian study, cutaneous basal-cell carcinomas developed in two patients (including one patient who had a history of basal-cell carcinoma) and a cutaneous superficial melanoma developed in one patient, all during treatment with vemurafenib. In the U.S. study, cutaneous squamouscell carcinomas developed in three patients (all of whom had a history of squamous-cell carcinoma) and a cutaneous basal-cell carcinoma developed in one patient. All these tumors were managed by simple excision.
A slight transient decrease in the hemoglobin level was noted in 10 patients in the Italian study within the first 6 weeks of treatment. Neutropenia was noted in 1 patient in the U.S. study.
In the Italian trial, the planned dose of vemurafenib (960 mg administered twice daily) was reduced for at least 3 weeks in 17 instances, involving 15 of 26 patients (58%), to 720 mg twice daily (9 patients), 480 mg twice daily (3 patients), or 240 mg twice daily (3 patients). Toxic effects that led to these dose reductions were mainly rash (in 6 patients) and increased creatinine or bilirubin level, arthralgia, pancreatitis, and palmar and plantar dysesthesia (in 1 patient each).
In the U.S. trial, 13 patients (50%) required reductions in the dose to 720 mg twice daily (2 patients), 480 mg twice daily (10 patients), or 240 mg twice daily (1 patient). Adverse events leading to dose modifications were arthralgia (in 5 patients), rash (in 5), photosensitivity (in 1), neutropenia (in 1), and elevations of the aspartate or alanine aminotransferase levels (in 1).
Pharmacodynamic Analyses and Resistance Mechanisms
Hairy-cell leukemia cells that are exposed to vemurafenib in vitro down-regulate CD25 and lose their surface projections. 16 Flow cytometry in blood and bone marrow consistently showed a loss of surface CD25 in a large fraction of leukemia cells at one or more time points during therapy in 15 of 19 patients (79%) who could be evaluated in the Italian study (including 1 patient for whom data have already been reported 16 ) (Fig. 3A) . This finding suggests that the measurement of surface or soluble CD25 may underestimate the residual burden of hairy-cell leuke- mia during vemurafenib treatment. In 1 patient with marked lymphocytosis, leukemic cells showed a clear smoothing of the cell membrane 2 and 3 days after the initiation of vemurafenib (Fig. 3B ). In 13 of 26 patients in the Italian study, a bone marrow-biopsy specimen obtained the day after the completion of therapy could be evaluated for phosphorylated ERK and PAX5 double immunostaining. In 6 of the 13 patients (all of whom had a partial response), residual hairy cells (PAX5 positive) that were still expressing phosphorylated ERK were observed, despite prolonged exposure (16 to 20 weeks) to vemurafenib ( Fig. 3C ). In 7 of the 13 patients (2 patients with a complete response and 5 with a partial response after 12 to 20 weeks of treatment), residual leukemic cells did not detectably express phosphorylated ERK (Fig. 3C) . In a post hoc exploratory analysis, the median progressionfree survival was 8 months (range, 5 to 13) in patients with residual phosphorylated ERK-positive leukemic cells and 13 months (range, 8 to 24) in patients without such cells (hazard ratio for disease progression, 10.33; 95% CI, 2.10 to 50.81; P = 0.004).
The residual disease, as measured by the Hairy Cell Index (ranging from 0 to 1, with * The adverse events listed here occurred in at least one patient in either trial. No grade 4 events were reported in either study. † In one patient, two basal-cell carcinomas developed; the other patient had a history of basal-cell carcinoma. ‡ All three patients had a history of squamous-cell carcinoma. § The patient with grade 2 pancreatitis in the Italian trial had an elevated lipase or amylase level (or both) but did not have clinical symptoms or radiologic abnormalities. higher values indicating greater leukemic infiltration), was higher in patients with persistent phosphorylated ERK in leukemic cells than in those with undetectable expression of phosphorylated ERK in leukemic cells (mean Hairy Cell Index, 0.139 vs. 0.054; P = 0.03 by a twosided Mann-Whitney test). Thus, persistent ERK phosphorylation in residual hairy cells at the end of treatment may indicate a greater burden of residual disease and shorter progression-free survival, which suggests that reactivation of MEK and ERK is a resistance mechanism to vemurafenib.
In the U.S. trial, before vemurafenib treatment, the mean percentage of leukemic cells in PBMCs and bone marrow mononuclear cells as assessed by means of flow cytometry was 16.0% and 16.8%, respectively. These values decreased to 3.4% and 6.9%, respectively, after 4 weeks of treatment ( Fig. 2C ) and to 0.7% and 4.2%, re-spectively, by 12 weeks (P<0.05 for all comparisons). The percentage of hairy cells in bone marrow decreased even further after 24 weeks to a mean of 1.3% (Fig. 2C) . Likewise, the droplet digital PCR assay, which was performed to quantify the concentration of molecules with mutated BRAF V600E DNA, revealed a decrease by a factor of more than 100 in the BRAF V600E allele burden in PBMCs after 12 weeks of vemurafenib therapy (P<0.001 for the comparison with the pretreatment value) (Fig. 2D) . Consistent with this finding, phosphorylated ERK1/2 rapidly decreased in bone marrow-biopsy specimens after 4 weeks of vemurafenib therapy (Fig.  S3A in the Supplementary Appendix) .
Finally, in all the patients, serum levels of soluble IL2RA and interleukin-1 receptor type II, which are well-established biomarkers of hairycell leukemia, 27, 28 declined markedly, as compared with baseline, by a mean of 30% and 27%, respectively, within 24 hours after the initiation of vemurafenib. After 3 months, the mean levels had declined by at least 95% ( Fig. S3B and S3C in the Supplementary Appendix).
In one patient in the U.S. study who had disease that was refractory to vemurafenib retreatment, targeted sequencing of 300 genes ( Table  S6 in the Supplementary Appendix) identified two separate activating subclonal KRAS mutations (along with a new RUNX1 mutation) at the time of relapse after the initial vemurafenib treatment, in addition to the recurrence of the BRAF V600E mutation. KRAS mutations had not been seen before vemurafenib treatment or at remission (day 120) despite high KRAS sequencing coverage (range, 496× to 1165×) ( Fig. 4B , and Table S5 in the Supplementary Appendix). Because in BRAF V600E-mutant cancers activating RAS mutations represent a known mechanism of vemurafenib resistance by means of the rephosphorylation of MEK and ERK, 29 the KRAS mutations that were newly acquired in this patient at relapse, although subclonal, probably contributed to the subsequent insensitivity to vemurafenib (Fig. 4C ).
Discussion
In these two trials involving patients with hairycell leukemia, an oral course of vemurafenib (at a dose of 960 mg twice daily for 16 to 18 weeks) was rapidly and highly effective, with response rates of 96% in the Italian study and 100% in the U.S. study and with low-grade toxic effects in patients who not only were heavily pretreated but often had disease that was refractory to their last therapy (56% of patients in the Italian study and 41% of those in the U.S. study). The median 
The New England Journal of Medicine time to response was 8 weeks in the Italian trial; the response rate was assessed at 12 weeks in the U.S. trial. A longer duration of treatment did not appear to improve the type or duration of the response. Retreatment with vemurafenib at the time of relapse was effective in the two trials, although to a lesser extent in the patients who had a relapse after a partial response than in those who had a relapse after a complete response in the Italian study. Rather than administering vemurafenib for an indefinite duration, as is done in patients with metastatic melanoma, [30] [31] [32] we limited the initial vemurafenib treatment to a few months (even if this perhaps reduced the type or duration of response) owing to concern about vemurafenibinduced secondary tumors. [33] [34] [35] Although such tumors affect primarily the skin and are of low malignant potential, their development may be less acceptable in patients with an indolent leukemia (however refractory or multiply relapsed) than in those with metastatic melanoma.
The rate, type, and duration of response that we observed among patients with hairy-cell leukemia were superior to those that have been observed in patients with metastatic melanoma, [30] [31] [32] possibly owing to the less complex genome landscape of hairy-cell leukemia (dominated by BRAF V600E 10 ) and the much lower proliferative index (≤1% of proliferating cells) of hairy-cell leukemia as compared with metastatic melanoma. 36, 37 However, in the U.S. trial, residual hairy cells in bone marrow with their associated BRAF V600E allele burden were consistently present at the end of treatment, even after a complete response. In approximately half the patients who could be evaluated in the Italian study, these cells showed persistent expression of phosphorylated ERK despite prolonged ongoing exposure to vemurafenib, which appeared to correlate with a higher burden of residual leukemia and shorter progression-free survival. This finding suggests that, in at least some patients, leukemic cells develop alternative mechanisms for reactivating MEK and ERK to bypass BRAF blockade.
In vitro studies conducted by the Italian group suggest that the bone marrow microenvironment might oppose vemurafenib-induced ERK dephosphorylation and apoptosis. 16 It was proposed 38 that as hairy cells pass through the vitronectinrich splenic red pulp, they receive vitronectinmediated proapoptotic signals that are transduced by activation of p38 and Jun N-terminal kinase (JNK) but are overcome by concomitant antiapoptotic signals from the constitutive activation of MEK and ERK. We found that prior splenectomy appeared to be associated with a shorter duration of response. Thus, a lack of hairy-cell recirculation through the spleen, resulting in their continuous homing to the protective bone marrow microenvironment, may favor the persistence of ERK phosphorylation in leukemic cells at the end of treatment -a feature that is also apparently associated with a shorter duration of response. Furthermore, two activating KRAS mutations developed in one patient in the U.S. trial who had a relapse, which probably contributed to disease progression during vemurafenib retreatment.
Vemurafenib-related adverse events were manageable and were similar to those observed in patients with melanoma (e.g., rash, arthralgias, and secondary cutaneous tumors). The absence of clinically significant myelotoxic effects makes vemurafenib an ideal salvage treatment for patients with multiply relapsed hairy-cell leukemia who have pancytopenia and scarce bone marrow reserve owing to previous chemotherapies.
In anecdotal cases, lower doses of vemurafenib (e.g., 240 mg twice daily) from the beginning of treatment proved effective in patients with relapsed or refractory hairy-cell leukemia. 17 One patient in the U.S. study had disease that was refractory to vemurafenib retreatment and underwent targeted sequencing of 300 genes. Panel A shows the serial flow-cytometric analysis of HCL cells in peripheralblood mononuclear cells (PBMCs) from this patient throughout the initial course of therapy (days 0 to 180) and vemurafenib retreatment (days 260 to 320). The sectioned-off areas in the fluorescence-activated cellsorting plots indicate HCL cells (CD19 and CD103), with percentages of HCL cells among the PBMCs. Panel B shows the somatic mutations that were identified in PBMCs after 0, 120, and 260 days of vemurafenib treatment. The variant allele frequency is shown for mutations seen at each time point. Panel C shows the percentage of HCL cells in peripheral blood (left axis) and the total white-cell count (right axis) in this patient. In our studies, the starting dose of 960 mg twice daily was reduced only if an unacceptable level of toxic effects occurred; in most cases, the dose was reduced to a twice-daily dose of 720 mg (in the Italian study) or 480 mg (in the U.S. study), followed sometimes by reescalation. Prospective clinical trials are needed to formally evaluate toxicity, response rate, and survival with lower vemurafenib doses or longer treatment durations than those we used in these trials. Clinical trials are also warranted to evaluate the other clinical BRAF inhibitor, dabrafenib, which in vitro studies by the Italian group 16 and single case reports 18, 39 have suggested to be effective in refractory or relapsed hairy-cell leukemia. We used vemurafenib as single agent. However, BRAF inhibitors could be combined with anti-CD20 monoclonal antibodies (e.g., rituximab) to potentially eradicate BRAF inhibitor-resistant hairy-cell leukemia cells. The finding of MAPKpathway reactivation as a likely mechanism of resistance to vemurafenib in some patients also establishes a rationale for combined BRAF and MEK blockade, which has been used successfully in patients with metastatic melanoma. 40 In conclusion, we found that vemurafenib is an active targeted drug for patients with relapsed or refractory hairy-cell leukemia.
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